Kura Oncology, INC. 8-K Filing
Ticker: KURA · Form: 8-K · Filed: Nov 13, 2025 · CIK: 1422143
| Field | Detail |
|---|---|
| Company | Kura Oncology, INC. (KURA) |
| Form Type | 8-K |
| Filed Date | Nov 13, 2025 |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $48,500 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Kura Oncology, INC. (ticker: KURA) to the SEC on Nov 13, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ich registered Common Stock, par value $0.0001 per share KURA The Nasdaq Global Se); $48,500 (t for a one-month supply of KOMZIFTI at $48,500. In November 2024, the Company and Ky).
How long is this filing?
Kura Oncology, INC.'s 8-K filing is 4 pages with approximately 1,178 words. Estimated reading time is 5 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,178 words · 5 min read · ~4 pages · Grade level 13.2 · Accepted 2025-11-13 16:27:09
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share KURA The Nasdaq Global Se
- $48,500 — t for a one-month supply of KOMZIFTI at $48,500. In November 2024, the Company and Ky
Filing Documents
- d159173d8k.htm (8-K) — 29KB
- 0001193125-25-280255.txt ( ) — 142KB
- kura-20251113.xsd (EX-101.SCH) — 3KB
- kura-20251113_lab.xml (EX-101.LAB) — 18KB
- kura-20251113_pre.xml (EX-101.PRE) — 11KB
- d159173d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements Any forward-looking statements in this Current Report on Form 8-K are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the risk that KOMZIFTI may have unintended side effects; risks associated with market competition, market acceptance and commercialization of KOMZIFTI; the risk that the collaboration with Kyowa Kirin is unsuccessful; and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs, as well as those risks and uncertainties set forth more fully under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 filed with the Securities and Exchange Commission ("SEC") on November 4, 2025, as well as discussions of potential risks, uncertainties and other important factors in the Company's other filings and reports with the SEC. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made. The Company undertakes no obligation t
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KURA ONCOLOGY, INC. Date: November 13, 2025 By: /s/ Teresa Bair Teresa Bair Chief Legal Officer